Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olov Wiklund

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
Gastroenterology|February 7, 2016
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European DescentRosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 2, 2017
New strategies for the development of lipid-lowering therapies to reduce cardiovascular riskIan Graham, Chuck Shear, Pieter De Graeff, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
Gastroenterology|February 7, 2016
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European DescentRosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 2, 2017
New strategies for the development of lipid-lowering therapies to reduce cardiovascular riskIan Graham, Chuck Shear, Pieter De Graeff, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|February 20, 2015
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and ManagementErik S Stroes, Paul D Thompson, Alberto Corsini, et al.
European Heart Journal|May 3, 2018
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataractFrançois Mach, Kausik K Ray, Olov Wiklund, et al.
Pageof 7